<< Back
Questcor Announces the Addition of George Stuart as Chief Financial Officer

UNION CITY, Calif.--(BUSINESS WIRE)--Sept. 28, 2005--Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical company, announced today that George Stuart has joined the company as Vice President of Finance and Chief Financial Officer.

"We are excited to have George join Questcor. His experience and abilities will be a welcome addition to the Questcor team. George's financial background and specialty pharmaceutical experience are an ideal fit for Questcor," stated Jim Fares, Questcor's President and CEO.

Mr. Stuart has 19 years of experience in finance including the last 6 years with specialty pharmaceutical companies. Mr. Stuart joins Questcor from Xcel Pharmaceuticals, Inc., where he was Vice President of Finance, Chief Financial Officer and Treasurer. He was a co-founder of Xcel, a private start up company, which he joined in 2001. He was a key contributor to Xcel's rapid growth and ultimately to Xcel's acquisition by Valeant Pharmaceuticals for $280 million. Prior to Xcel, Mr. Stuart was Director of Corporate Accounting for Ligand Pharmaceuticals, Inc. Before joining Ligand in early 1999, Mr. Stuart worked for Deloitte & Touche LLP as a Senior Manager. Mr. Stuart received his bachelor's degree from San Diego State University in Accounting and is a Certified Public Accountant.

Mr. Stuart will be responsible for Questcor's Finance and Administration functions.

About Questcor

Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets four products in the U.S.: H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug that is commonly used for certain neurological conditions; Nascobal(R), the only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin B12), that is approved for patients with B12 deficiency caused by malabsorptive disorders resulting from structural or functional damage, such as bariatric surgery, Crohn's disease and certain neurological conditions; Ethamolin(R) (Ethanolamine Oleate), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; and Glofil-125(R), which is an injectable agent that assesses how well the kidney is working by measuring glomerular filtration rate, or kidney function.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast and create the demand for each of its products, the gross margins achieved from the sale of those products, Questcor's ability to enforce its exchange policy, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's need for additional funding, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and, to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's annual report on Form 10-K for the calendar year ended December 31, 2004 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


CONTACT:
Questcor Pharmaceuticals, Inc.
James L. Fares,
510-400-0700
SOURCE: Questcor Pharmaceuticals, Inc.

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\89\89528\Disclaimers.xml'.